Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Clinical Journal of the American Society of Nephrology : CJASN
|
May 24, 2020
Apixaban versus No Anticoagulation in Patients Undergoing Long-Term Dialysis with Incident Atrial Fibrillation
Thomas A Mavrakanas, Katherine Garlo, David M Charytan
Clinical Nephrology. Case Studies
|
October 19, 2017
Successful eculizumab treatment of recurrent postpartum atypical hemolytic uremic syndrome after kidney transplantation
Katherine Garlo, Doug Dressel, Marizela Savic, et al.
Journal of the American Geriatrics Society
|
November 20, 2010
Burden in caregivers of older adults with advanced illness
Katherine Garlo, John R O'Leary, Peter H Van Ness, et al.
Kidney Medicine
|
July 7, 2023
Atypical Hemolytic Uremic Syndrome Treated With Ravulizumab or Eculizumab: A Claims-Based Evaluation of Health Care Resource Utilization and Clinical Outcomes in the United States
Yan Wang, Imad Al-Dakkak, Katherine Garlo, et al.
Medicine
|
June 25, 2015
Severity of Anemia Predicts Hospital Length of Stay but Not Readmission in Patients with Chronic Kidney Disease: A Retrospective Cohort Study
Katherine Garlo, Deanna Williams, Lee Lucas, et al.
Molecular Diagnosis & Therapy
|
November 4, 2022
Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab
Tobin J Cammett, Katherine Garlo, Ellen E Millman, et al.
Kidney International Reports
|
June 25, 2021
Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults
Thomas Barbour, Marie Scully, Gema Ariceta, et al.
Journal of Comparative Effectiveness Research
|
July 29, 2023
Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome
Teri J Mauch, Michael R Chladek, Spero Cataland, et al.
Kidney Medicine
|
August 6, 2024
Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials
Bradley P Dixon, David Kavanagh, Alvaro Domingo Madrid Aris, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Clinical Journal of the American Society of Nephrology : CJASN
|
May 24, 2020
Apixaban versus No Anticoagulation in Patients Undergoing Long-Term Dialysis with Incident Atrial Fibrillation
Thomas A Mavrakanas, Katherine Garlo, David M Charytan
Clinical Nephrology. Case Studies
|
October 19, 2017
Successful eculizumab treatment of recurrent postpartum atypical hemolytic uremic syndrome after kidney transplantation
Katherine Garlo, Doug Dressel, Marizela Savic, et al.
Journal of the American Geriatrics Society
|
November 20, 2010
Burden in caregivers of older adults with advanced illness
Katherine Garlo, John R O'Leary, Peter H Van Ness, et al.
Kidney Medicine
|
July 7, 2023
Atypical Hemolytic Uremic Syndrome Treated With Ravulizumab or Eculizumab: A Claims-Based Evaluation of Health Care Resource Utilization and Clinical Outcomes in the United States
Yan Wang, Imad Al-Dakkak, Katherine Garlo, et al.
Medicine
|
June 25, 2015
Severity of Anemia Predicts Hospital Length of Stay but Not Readmission in Patients with Chronic Kidney Disease: A Retrospective Cohort Study
Katherine Garlo, Deanna Williams, Lee Lucas, et al.
Molecular Diagnosis & Therapy
|
November 4, 2022
Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab
Tobin J Cammett, Katherine Garlo, Ellen E Millman, et al.
Kidney International Reports
|
June 25, 2021
Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults
Thomas Barbour, Marie Scully, Gema Ariceta, et al.
Journal of Comparative Effectiveness Research
|
July 29, 2023
Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome
Teri J Mauch, Michael R Chladek, Spero Cataland, et al.
Kidney Medicine
|
August 6, 2024
Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials
Bradley P Dixon, David Kavanagh, Alvaro Domingo Madrid Aris, et al.
Page
of 1